Home » Services » Diet Pills

Diet Pills

Are Diet Pills or Supplements for Weight Loss Right For Me?

In addition to therapeutic lifestyle changes and medical nutrition plans, weight loss medications may be needed to get the results you are looking for. They come in several categories. Two prominent categories include appetite suppressants, also called anorectics, and those that cause malabsorption.

adipex-p diet pill

adipex-p diet pill

A drug called Orlistat, now under the brand name Alli®, which is available over-the-counter, is a drug that inhibits pancreatic lipase, an enzyme that breaks down fat and decreases fat absorption. There are other medications that have been approved for short term use at three month intervals.

Phentermine, which is generic for Adipex® and diethylproprion, which is generic for Tenuate®, are popular drugs used for their appetite suppressing qualities. Both phentermine and diethylproprion are controlled substances and may have side-effects.

New FDA approved weight loss medication Qsymia

We are also happy to announce that we prescribe Qsymia™, a newly FDA approved medication for weight loss. W8MD can offer the brand name Qsymia or the generic combination with Phentermine an Topamax at a dollar a pill when medically appropriate as determined by the weight loss doctor after the consultation.

Cost of Qsymia – Generic combination versus Brand name
The manufacturer cost of Qsymia retailed through various pharmacies is approximately &160.00 per month. Due to this steep price, some patients of W8MD Medical Weight Loss Centers requested if they can try the generic combination (Phentermine and Topiramate) as both the ingredients are generic and we had good success in trying the generic combination. Since each of these two components can be obtained for about a dollar a pill each, with a total monthly cost of $60.00 USD for Qsymia, it works out much cheaper to do the generic Qsymia combination compared to the brand price.

Here is the information from the FDA regarding Qsymia weight loss medication.

The U.S. Food and Drug Ad ministration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity and overweight categories. According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.

“Obesity threatens the overall well being of patients and is a major public health concern,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition.”

w8md diet pills

w8md diet pills

Qsymia is a combination of two FDA-approved drugs, phentermine and topiramate, in an extended-release formulation. Phentermine is indicated for short-term weight loss in overweight or obese adults who are exercising and eating a reduced calorie diet. Topiramate is indicated to treat certain types of seizures in people who have epilepsy and to prevent migraine headaches.

Qsymia must not be used during pregnancy because it can cause harm to a fetus. Data show that a fetus exposed to topiramate, a component of Qsymia, in the first trimester of pregnancy has an increased risk of oral clefts (cleft lip with or without cleft palate). Females of reproductive potential must not be pregnant when starting Qsymia therapy or become pregnant while taking Qsymia. Females of reproductive potential should have a negative pregnancy test before starting Qsymia and every month while using the drug and should use effective contraception consistently while taking Qsymia.

The safety and efficacy of Qsymia were evaluated in two randomized, placebo-controlled trials that included approximately 3,700 obese and overweight patients with and without significant weight-related conditions treated for one year. All patients received lifestyle modification that consisted of a reduced calorie diet and regular physical activity.

The recommended daily dose of Qsymia contains 7.5 milligrams of phentermine and 46 mg of topiramate extended-release. Qsymia is also available at a higher dose (15 mg phentermine and 92 mg of topiramate extended-release) for select patients.

Results from the two trials show that after one year of treatment with the recommended and highest daily dose of Qsymia, patients had an average weight loss of 6.7 percent and 8.9 percent, respectively, over treatment with placebo. Approximately 62 percent and 69 percent of patients lost at least five percent of their body weight with the recommended dose and highest dose of Qsymia, respectively, compared with about 20 percent of patients treated with placebo.

The recommended daily dose of Qsymia contains 7.5 milligrams of phentermine and 46 mg of topiramate extended-release. Qsymia is also available at a higher dose (15 mg phentermine and 92 mg of topiramate extended-release) for select patients.

Results from the two trials show that after one year of treatment with the recommended and highest daily dose of Qsymia, patients had an average weight loss of 6.7 percent and 8.9 percent, respectively, over treatment with placebo. Approximately 62 percent and 69 percent of patients lost at least five percent of their body weight with the recommended dose and highest dose of Qsymia, respectively, compared with about 20 percent of patients treated with placebo.

Patients who did not lose at least three percent of their body weight by week 12 of treatment with Qsymia were unlikely to achieve and sustain weight loss with continued treatment at this dose. Therefore, response to therapy with the recommended daily dose of Qsymia should be evaluated by 12 weeks to determine, based on the amount of weight loss, whether to discontinue Qsymia or increase to the higher dose.  If after 12 weeks on the higher dose of Qsymia, a patient does not lose at least five percent of body weight, then Qsymia should be discontinued, as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment.

Amazing weight loss results

Amazing weight loss results

Qsymia must not be used in patients with glaucoma or hyperthyroidism. Qsymia can increase heart rate; this drug’s effect on heart rate in patients at high risk for heart attack or stroke is not known. Therefore, the use of Qsymia in patients with recent (within the last six months) or unstable heart disease or stroke is not recommended. Regular monitoring of heart rate is recommended for all patients taking Qsymia, especially when starting Qsymia or increasing the dose.

The FDA approved Qsymia with a Risk Evaluation and Mitigation Strategy (REMS), which consists of a Medication Guide advising patients about important safety information and elements to assure safe use that include prescriber training and pharmacy certification. The purpose of the REMS is to educate prescribers and their patients about the increased risk of birth defects associated with first trimester exposure to Qsymia, the need for pregnancy prevention, and the need to discontinue therapy if pregnancy occurs. Qsymia will only be dispensed through specially certified pharmacies.

Vivus Inc. will be required to conduct 10 postmarketing requirements, including a long-term cardiovascular outcomes trial to assess the effect of Qsymia on the risk for major adverse cardiac events such as heart attack and stroke.

The most common side effects of Qsymia are tingling of hands and feet (paresthesia), dizziness, altered taste sensation, insomnia, constipation, and dry mouth.

Qsymia is marketed by Vivus Inc. in Mountain View, Calif.

Orlistat Orlistat (Xenical) reduces intestinal fat absorption by inhibiting pancreatic lipase. Some side-effects of using Orlistat include frequent, oily bowel movements (steatorrhea). But if fat in the diet is reduced, symptoms often improve. Originally available only by prescription, it was approved by the FDA for over-the-counter sale in February 2007. On 26 May 2010, the U.S. Food and Drug Administration (FDA) has approved a revised label for Xenical to include new safety information about cases of severe liver injury that have been reported rarely with the use of this medication. Of the 40 million users of Orlistat worldwide, 13 cases of severe liver damage have been reported.

Lorcaserin (Belviq for weight loss) was approved June 28, 2012 for obesity with other co-morbidities. The average weight loss by study participants was modest, but the most common side effects of the drug are considered benign.

 

Prescription diet pills

Prescription diet pills

An excerpt from the Bloom 1 Study conducted by Arena Pharmaceuticals and later submitted for FDA approval:

At the end of Year 1 of the BLOOM trial, using Intent-to-Treat with Last Observation Carried Forward analysis (ITT-LOCF), the proportion of patients achieving at least 5% body weight loss in the lorcaserin group (47.5%) was more than twice that achieved by the placebo group (20.3%).

Nearly three times as many patients achieved at least 10% weight loss in the lorcaserin group (22.6%) than in the placebo group (7.7%). Lorcaserin patients who completed the first year of the trial according to the protocol lost an average of 8.2% of their baseline weight, or approximately 18 pounds, at the end of Year 1 as compared to approximately 7 pounds in the placebo group. In Year 2, patients who continued to take lorcaserin were significantly better able to maintain their Year 1 weight loss than those who were switched to placebo.

In Year 1, lorcaserin caused significant decreases in waist circumference, BMI, glycemic parameters, high-sensitivity C-reactive protein, and fibrinogen levels compared to placebo. Total cholesterol, LDL cholesterol and triglyceride levels at Year 1 were significantly lower in the lorcaserin group than in the placebo group. Lorcaserin did not increase heart rate or blood pressure; rather, heart rate, systolic blood pressure and diastolic blood pressure decreased slightly but significantly with lorcaserin treatment compared to placebo. Quality of life, measured by the Impact of Weight on Quality of Life-Lite questionnaire, improved in both treatment groups, with a greater improvement in the lorcaserin group than in the placebo group.

At the end of Year 1, 55.4% of patients in the lorcaserin group and 45.1% of patients in the placebo group remained enrolled in the study, and 7.1% and 6.7% of patients, respectively, discontinued the study due to an adverse event. Among the most frequent adverse events reported with lorcaserin were headache (18.0% vs. 11.0%, lorcaserin vs. placebo); dizziness (8.2% vs. 3.8%); and nausea (7.5% vs. 5.4%). The rates of serious adverse events were similar in both treatment groups. The rates of depression and the incidence of anxiety and suicidal thoughts were low in both treatment groups. Lorcaserin caused no significant increase compared to placebo in the incidence of new cardiac valvulopathy.

New weight loss drugs approved in 2015

Rimonabant weigth loss medication (Acomplia) is a recently developed anti-obesity medication. It is cannabinoid (CB1) receptor antagonist that acts centrally on the brain thus decreasing appetite. It may also act peripherally by increasing thermogenesis and therefore increasing energy expenditure.

Weight loss with Rimonabant however has not been shown to be greater than other available weight-loss medication. Due to safety concerns, primarily psychiatric in nature, the drug has not received approval in the United States or Canada, either as an anti-obesity treatment or as a smoking-cessation drug.

Sanofi-Aventis has received approval to market Rimonabant as a prescription anti-obesity drug in the European Union, subject to some restrictions. However, in October 2008, the European Medicines Agency (EMEA) recommended that Acomplia no longer be available in UK. One month later, Sanofi-Aventis decided it would no longer study rimonabant for any indication.

Metformin In people with Diabetes mellitus type 2, the drug metformin (Glucophage) can reduce weight. Metformin limits the amount of glucose that is produced by the liver as well as increases muscle consumption of glucose.

W8MD medical weight loss centers insurance weight loss program

W8MD medical weight loss centers insurance weight loss program

Exenatide Exenatide (Byetta) is a long-acting analogue of the hormone GLP-1, which the intestines secrete in response to the presence of food. Among other effects, GLP-1 delays gastric emptying and promotes a feeling of satiety. Some obese people are deficient in GLP-1, and dieting reduces GLP-1 further.

Pramlintide (Symlin) is a synthetic analogue of the hormone Amylin, which in normal people is secreted by the pancreas in response to eating. Among other effects, Amylin delays gastric emptying and promotes a feeling of satiety. A drawback is that Symlin must be injected at mealtimes.

Other drugs Other weight loss drugs hav

Alternative medicine Most supplements and alternative medicine has insufficient evidence to support or oppose its use.

 Conjugated linoleic acid for weight loss: It is claimed to reduce body fat. It is possibly effective. The side effects include ppset stomach, nausea, loose stools
Green tea extract for weight loss: The claim is that it helps decrease appetite, and increases metabolism, fat cell death. There is insufficient evidence to evaluate this in studies. Side effects of this medication include Dizziness, insomnia, agitation, nausea, vomiting, bloating, gas, diarrhea

Khat weight loss supplement: The claim is that it reduces appetite. It’s long term use (high dosage) may cause liver damage, heart problems
Lipoic acid for weight loss: The claim is that it increases glucose absorption in muscles rather than fat.

ECA Stack for weight loss: The claim is that it increases metabolism. Side effects include severe skin reactions, irritability, nervousness, dizziness, trembling, headache, insomnia, profuse perspiration, dehydration, itchy scalp and skin, vomiting, hyperthermia, irregular heartbeat, seizures, heart attack, stroke, or death.

Raspberry ketone for weight loss: The claim is that it increases norepinephrine-induced lipolysis. There are no large studies to show clinical evidence in humans.

zocdoc-patient-reviews-dr-prab-r-tumpati-md

Risks and Benefits
While there are risks and benefits to almost anything in life, one benefit you will find at Dr. Tumpati’s W8MD Medical Weight Loss Center is knowledgeable staff that will take the time to review these medications with you. Ultimately it is up to you and your health provider to safely add medication to any weight loss program.

Weight Loss Medications are only useful for those already on a healthy lifestyle program who are not losing weight as expected. They are especially beneficial for people with BMI of 27 or greater, who are concerned about their weight, disease risk and current health status.
No matter which program you choose, we are excited t

o be on your team. Numerous programs place emphasis on vitamin pills or herbs. They may promote certain medications, injections or surgery. Our programs are so flexible they work with any program you may be on. For example, you may want to add medication to the benefits of Weight Watchers® or Jenny Craig®. Any program you use that is effective for you can be continued.

At Dr. Tumpati’s W8MD Medical Weight Loss Center we put the person first above all else. When you are first, you can’t lose. We will give the choices with no obligations, setup fees or mandatory products, with insurances accepted for weight loss visits.

This is so affordable compared to $325.00 consultations from some of the “Cash Only” weight loss clinics!

 Weight Loss Prescription Diet Pills

Success Stories | Videos | Benefits of weight loss

6 Responses so far.

  1. […] Combination of Phentermine and Topiramate like in the brand name Qsymia available at W8MD for a low price of $30.oo per month supply for […]
  2. […] Combination of Phentermine and Topiramate like in the brand name Qsymia available at W8MD for a low price of $30.oo per month supply for […]

Leave a Reply